204 related articles for article (PubMed ID: 22257653)
1. Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review.
Arcangeli S; Scorsetti M; Alongi F
Crit Rev Oncol Hematol; 2012 Oct; 84(1):101-8. PubMed ID: 22257653
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic body radiation therapy (SBRT) for genitourinary malignancies.
Teh BS; Ishiyama H; Mathews T; Xu B; Butler EB; Mayr NA; Lo SS; Lu JJ; Blanco AI; Paulino AC; Timmerman RD
Discov Med; 2010 Sep; 10(52):255-62. PubMed ID: 20875347
[TBL] [Abstract][Full Text] [Related]
3. [Recent developments in radiation oncology-integrating radiation physics and molecular radiobiology advances into clinical radiotherapy practice and beyond].
Teh BS; Paulino A; Butler EB
Ai Zheng; 2008 Aug; 27(8):885-93. PubMed ID: 18710628
[TBL] [Abstract][Full Text] [Related]
4. Emerging application of stereotactic body radiation therapy for gynecologic malignancies.
Mayr NA; Huang Z; Sohn JW; Lo SS; Teh BS; Lu JJ; Grecula JC; Kunos C
Expert Rev Anticancer Ther; 2011 Jul; 11(7):1069-75. PubMed ID: 21806330
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiation therapy for prostate cancer: is the technology ready to be the standard of care?
Zaorsky NG; Studenski MT; Dicker AP; Gomella L; Den RB
Cancer Treat Rev; 2013 May; 39(3):212-8. PubMed ID: 23218442
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.
King CR; Brooks JD; Gill H; Presti JC
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):877-82. PubMed ID: 21300474
[TBL] [Abstract][Full Text] [Related]
7. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
Lunsford LD; Flickinger JC; Larson D
Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer.
Lanni TB; Grills IS; Kestin LL; Robertson JM
Am J Clin Oncol; 2011 Oct; 34(5):494-8. PubMed ID: 20805737
[TBL] [Abstract][Full Text] [Related]
9. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations.
Fuller DB; Naitoh J; Lee C; Hardy S; Jin H
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1588-97. PubMed ID: 18374232
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee.
Buyyounouski MK; Price RA; Harris EE; Miller R; Tomé W; Schefter T; Parsai EI; Konski AA; Wallner PE
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1297-304. PubMed ID: 20338473
[No Abstract] [Full Text] [Related]
11. Stereotactic body radiation therapy: a novel treatment modality.
Lo SS; Fakiris AJ; Chang EL; Mayr NA; Wang JZ; Papiez L; Teh BS; McGarry RC; Cardenes HR; Timmerman RD
Nat Rev Clin Oncol; 2010 Jan; 7(1):44-54. PubMed ID: 19997074
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
King CR; Brooks JD; Gill H; Pawlicki T; Cotrutz C; Presti JC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1043-8. PubMed ID: 18755555
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic body radiotherapy for prostate cancer.
Henderson DR; Tree AC; van As NJ
Clin Oncol (R Coll Radiol); 2015 May; 27(5):270-9. PubMed ID: 25707911
[TBL] [Abstract][Full Text] [Related]
14. The use of stereotactic body radiation therapy in gastrointestinal malignancies in locally advanced and metastatic settings.
Khrizman P; Small W; Dawson L; Benson AB
Clin Colorectal Cancer; 2010 Jul; 9(3):136-43. PubMed ID: 20643617
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiation therapy for prostate cancer.
Ishiyama H; Teh BS; Lo SS; Mathews T; Blanco A; Amato R; Ellis RJ; Mayr NA; Paulino AC; Xu B; Butler BE
Future Oncol; 2011 Sep; 7(9):1077-86. PubMed ID: 21919695
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiation therapy for prostate cancer-a review.
Haque W; Butler EB; Teh BS
Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S10. PubMed ID: 28917248
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiotherapy: a critical review for nonradiation oncologists.
Kirkpatrick JP; Kelsey CR; Palta M; Cabrera AR; Salama JK; Patel P; Perez BA; Lee J; Yin FF
Cancer; 2014 Apr; 120(7):942-54. PubMed ID: 24382744
[TBL] [Abstract][Full Text] [Related]
18. Pushing the limits of radiation therapy for prostate cancer: where do we go next?
Mishra MV; Showalter TN
Semin Oncol; 2013 Jun; 40(3):297-307. PubMed ID: 23806495
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study.
Miralbell R; Mollà M; Rouzaud M; Hidalgo A; Toscas JI; Lozano J; Sanz S; Ares C; Jorcano S; Linero D; Escudé L
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):50-7. PubMed ID: 19910135
[TBL] [Abstract][Full Text] [Related]
20. A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy.
Myrehaug S; Chan G; Craig T; Weinberg V; Cheng C; Roach M; Cheung P; Sahgal A
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e657-62. PubMed ID: 22245189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
